台灣臨床試驗主持人資料庫|TPIDB

2017-06-30 - 2027-09-30

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
4Sites

Terminated4Sites

夏和雄

Taipei Medical University Hospital

Division of Hematology & Oncology

2016-11-01 - 2025-12-31

Others

Completed

Condition/Disease
Test Drug

Participate Sites
12Sites

Terminated11Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-09-01 - 2021-12-31

Phase I

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Condition/Disease

Breast Cancer
Test Drug

Oraxol

Participate Sites
7Sites

Terminated6Sites

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

趙大中

Taipei Veterans General Hospital

Division of Radiation Therapy

2018-03-01 - 2023-12-31

Phase III

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Condition/Disease

Hepatocellular Carcinoma (HCC)
Test Drug

Atezolizumab; Bevacizumab; Sorafenib

Participate Sites
5Sites

Terminated5Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-09-01 - 2020-11-09

Phase II

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR ATEZOLIZUMAB-PLACEBO IN PATIENTS WITH HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB AND TAXANE BASED THERAPY.

Condition/Disease

HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
Test Drug

KADCYLA

Participate Sites
10Sites

Terminated8Sites

侯明鋒

Kaohsiung Municipal Gangshan Hospital

未分科

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2016-02-21 - 2020-12-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE NEGATIVE BREAST CANCER

Condition/Disease

Triple Negative Breast Cancer (TNBC)
Test Drug

Atezolizumab

Participate Sites
6Sites

Not yet recruiting1Sites

Terminated3Sites

侯明鋒

Kaohsiung Municipal Gangshan Hospital

未分科

曾令民

Taipei Veterans General Hospital

Division of General Surgery

2015-10-22 - 2019-12-31

Phase III

A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients

Condition/Disease

Squamous Cell Head and Neck Cancer
Test Drug

MEDI4736; Tremelimumab

Participate Sites
8Sites

Terminated7Sites

謝清昀

China Medical University Hospital-Taipei

未分科

楊慕華

Taipei Veterans General Hospital

Division of Otolaryngology

2015-01-01 - 2017-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis

Condition/Disease

Chronic Kidney Disease
Test Drug

Roxadustat

Participate Sites
12Sites

Study ended12Sites

洪振傑

Linkou Chang Gung Medical Foundation

Division of Nephrology

唐德成

Taipei Veterans General Hospital

Division of Nephrology

2017-10-01 - 2021-03-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone

Condition/Disease

Type 2 Diabetes Mellitus
Test Drug

CS02 Tablet

Participate Sites
13Sites

Recruiting2Sites

Terminated10Sites

陳清助

China Medical University Hospital-Taipei

未分科

陳涵栩

Taipei Veterans General Hospital

Division of Endocrinology

2019-02-01 - 2020-12-31

Phase I

A Phase 1, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetic and efficacy of NBM-BMX in subjects with advanced solid tumors

Condition/Disease

Malignant Neoplasm
Test Drug

NBM-BMX

Participate Sites
2Sites

Recruiting2Sites

葉裕民

National Taiwan University Hospital

Division of Hematology & Oncology

顏厥全

Taipei Veterans General Hospital

Division of Hematology & Oncology

Search Result

List